The FDA has granted its breakthrough drug quizartinib a breakthrough treatment. Quizartinib is a FLT3 inhibitor under investigation for the treatment of adult patients with relapsed / refr...
The US Food and Drug Administration approved Venetoclax (Venclexta) combined with rituximab (VenR) for the treatment of patients with chronic lymphocytic leukemia (CLL) based on the minimal residual d...
According to the results of the second phase of the study, the combination of standard-care chemotherapy drug azacitidine and the immune checkpoint inhibitor nivolumab ( nivolumab ) showed that the...
The US FDA has approved gilteritinib ( Xospata ) for the treatment of adult patients with FLT3 mutation-positive relapse or refractory acute myeloid leukemia ( AML&n...
The results of a multi-center phase III clinical trial showed that if elderly patients with chronic lymphocytic leukemia ( CLL ) are treated with a new targeted drug ibrutinib comp...
Venetoclax (Venclexta) and rituximab (Rituxan) are used in combination with relapsed / refractory chronic lymphocytic leukemia ( CLL ), resulting in a high rate of undetectable minimal residual d...
LeukemiaIn the clinical field of medicine, leukemia is also called blood cancer and belongs to the category of malignant tumors. It is mainly divided into two types: acute leukemia and chronic leukemi...
People who know nothing about leukemia are the most frightened. They will definitely mix sepsis and leukemia. They think this is a disease. In fact, these are two different diseases. Leukemia is more ...
Rusotinib tablets (ruxolitinib / Jakafi) for the treatment of bone marrow fibrosis with moderate or high risk, including primary bone marrow fibrosis, myelofibrosis after polycythemia vera, and myelo...
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered a restrictive understanding and research consent to develop and market chimeric antigen recepto...